Please assess the completion status of the following clinical trial:

Trial Title: RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Be greater than or equal to 18 years of age of either sex or any race;~2. Have undergone unilateral cataract extraction via phacoemulsification on the day prior to study enrollment/randomization;~3. Have a grade of ≥2 in anterior chamber cell score on day after surgery (Day 1);~4. Have a potential post-operative pin-hole visual acuity (VA) of greater than 1.0 logarithm of the minimum angle of resolution (logMAR) in the operative eye and fellow eye as measured using an Early Treatment for Diabetic Retinopathy Study (ETDRS) chart;~Exclusion Criteria:~1. Have any intraocular inflammation present in the study eye during the screening slit lamp examination;~2. Have a score greater than 0 on the Ocular Pain Assessment at Screening in the study eye;~3. Have an immunosuppressive disease or an autoimmune disease that in the opinion of the Investigator could affect the quality of the ocular surface;~4. Have active or chronic/recurrent ocular or systemic disease that is uncontrolled and will likely affect wound healing;~5. Have an intraocular pressure (IOP) ≤ 5 mmHg in either eye;~6. Require the use of a contact lens or a collagen shield within 72 hours of investigational drug treatment or during the study period in the study eye; be unwilling to discontinue use of contact lenses during study period in the study eye;~7. Require use of non-diagnostic topical ophthalmic solutions (other than perioperative mydriatics, anesthetics and antiseptics, prophylactic antibiotics, lid scrubs for mild blepharitis, or artificial tears for the management of dry eye) in the study eye for the duration of the study;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omaveloxolone Ophthalmic Suspension 1.0% (Type: EXPERIMENTAL): Patients will receive a single drop of Omaveloxolone Ophthalmic suspension 1.0% instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery
- Omaveloxolone Ophthalmic Suspension 0.5% (Type: EXPERIMENTAL): Patients will receive a single drop of Omaveloxolone Ophthalmic suspension 0.5% instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive a single drop of vehicle for Omaveloxolone Ophthalmic suspension was instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).